Primecap Management Co. CA Has $2.38 Million Holdings in Cerus Co. (NASDAQ:CERS)

Primecap Management Co. CA lessened its holdings in shares of Cerus Co. (NASDAQ:CERS - Free Report) by 81.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,544,300 shares of the biotechnology company's stock after selling 6,999,700 shares during the period. Primecap Management Co. CA owned 0.83% of Cerus worth $2,378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CERS. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Cerus in the 3rd quarter valued at about $353,000. Intech Investment Management LLC acquired a new stake in shares of Cerus in the 3rd quarter valued at $71,000. Charles Schwab Investment Management Inc. raised its position in shares of Cerus by 0.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,754,540 shares of the biotechnology company's stock worth $3,053,000 after acquiring an additional 8,707 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in shares of Cerus by 1,182.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 132,628 shares of the biotechnology company's stock valued at $231,000 after acquiring an additional 122,290 shares during the period. Finally, FMR LLC boosted its holdings in Cerus by 23.7% in the third quarter. FMR LLC now owns 541,220 shares of the biotechnology company's stock valued at $942,000 after acquiring an additional 103,596 shares during the last quarter. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Cerus Trading Up 2.0 %

CERS traded up $0.03 during trading on Monday, reaching $1.56. 749,279 shares of the company's stock were exchanged, compared to its average volume of 1,225,573. The company's fifty day moving average price is $1.71 and its 200-day moving average price is $1.74. The firm has a market capitalization of $289.83 million, a PE ratio of -14.18 and a beta of 1.56. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.54. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59.

Remove Ads

Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The business had revenue of $50.81 million for the quarter, compared to analyst estimates of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. As a group, equities analysts forecast that Cerus Co. will post -0.08 EPS for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $4.00 price objective on shares of Cerus in a report on Friday, February 21st.

Insider Activity

In other Cerus news, insider Richard J. Benjamin sold 18,949 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $1.45, for a total value of $27,476.05. Following the completion of the sale, the insider now directly owns 715,850 shares in the company, valued at $1,037,982.50. This represents a 2.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Dennis Green sold 60,656 shares of Cerus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $1.58, for a total value of $95,836.48. Following the transaction, the chief financial officer now owns 493,862 shares in the company, valued at $780,301.96. This trade represents a 10.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 441,150 shares of company stock valued at $665,210 in the last ninety days. 3.40% of the stock is owned by insiders.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.